- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
SHANGHAI, Dec. 29, 2016 — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it had received the 2016 Asia Pacific Biologics CMO Growth Excellence Leadership Award from Frost & Sullivan, a leading business research and consulting firm.
Growth Excellence Leadership Award is part of the Frost & Sullivan Asia Pacific Best Practices Awards series, which identify and honor best-in-class companies in Asia Pacific that demonstrate excellence. WuXi Biologics has been recognized for its strong growth performance and customer impact in the region. Frost & Sullivan cited WuXi Biologics’ above market, sustainable company growth, its strong ownership and superb service experience for customers.
“WuXi Biologics is one of the most research-driven, experienced, and technologically advanced participants in the APAC region.” said Sanjeev Kumar, consultant at Frost & Sullivan’s Asia Pacific Transformational Health Practice. “The company has emerged as a preferred partner for customers with its broad therapeutic expertise, experience in navigating global regulations, and state-of-the-art systems scaled to client needs. The company has transformed itself into a fully Integrated Biologics Discovery, Development and Manufacturing Service Provider. For sustained growth, the company is investing wisely, broadly, and aggressively into building new capabilities and increasing capacity.”
“WuXi Biologics is honored to be recognized by Frost & Sullivan,” said Dr. Chris Chen, CEO of WuXi Biologics, “The award truly reflects all of the efforts we have put forth to provide our customers with high-quality and best-in-class service to help accelerate biologics development from concept to commercialization.”